Page 422 - Binder2

• Reduced carbon footprints in a climate-
constrained era.
• And most importantly, healthcare that belongs to
the people it serves.

This is not a detour from scientific rigor.
It is a return to public accountability.

Instead of waiting for access, communities grow it.

Redefining “Do No Harm”

In a world of edible biologics, “harm” must be understood
broadly:

• Harm is a price tag that denies a child with
Crohn’s disease the medicine they need.
• Harm is a patent that blocks a low-cost biosimilar
from entering a regional market.
• Harm is a cold chain that breaks in a border
crossing, rendering life-saving therapy inert.

So the new Hippocratic test must ask not only:

• Is this safe for the body?

But also:

• Is this sustainable for the system?
• Is this reachable by the patient?
• Is this therapy built for equity, not just for efficacy?

If the answer to those questions is no—then the therapy
may be scientifically sound, but it is ethically unsound.

420